FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company Profile20/20 Biolabs Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AIDX
20/20 Biolabs Inc. Stock AnalysisComprehensive stock analysis for 20/20 Biolabs Inc. (AIDX) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAIDX
AIDX
20/20 Biolabs Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AIDX
  1. Home
  2. Stocks
  3. 20/20 Biolabs Inc.

20/20 Biolabs Inc.

🇺🇸AIDX•NASDAQ

20/20 Biolabs Inc.

🇺🇸AIDX•NASDAQ
Market cap
$2.20M

Your view on AIDX

Mkt Cap
$2.20M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About 20/20 Biolabs Inc.

Industry
Medical - Care Facilities
Sector
Healthcare
CEO
Jonathan Cohen
Headquarters
15810 Gaither Road, Gaithersburg, MD, US
Industry
Medical - Care Facilities
Sector
Healthcare
CEO
Jonathan Cohen
Headquarters
15810 Gaither Road, Gaithersburg, MD, US
Description

20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test.

It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market.

The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.

Financial Data

Stock Data

Price chart, volume, and trading data.

What moved it

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for 20/20 Biolabs Inc.. Starting points for 20/20 Biolabs Inc.: EPS -$0.49, beta 1.54 — an Medical - Care Facilities name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for 20/20 Biolabs Inc.. Trailing twelve-month EPS for 20/20 Biolabs Inc. stands at -$0.49. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
Analysts' target$5.00average of analysts' targets
Current price—

Targets, low to high

$5.00

Low $5.00

Middle $5.00

High $5.00

More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.07$0.00−$0.52−$0.38
Lowest estimate−$0.07$0.00−$0.52−$0.38
Highest estimate−$0.07$0.00−$0.52−$0.38
Number of analysts1011
A year ago—−$0.281——
Growth vs a year ago————

1The year-ago figure includes one-time items, so growth is not shown.

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$896000.00$1.33M$2.62M$5.77M
Lowest estimate$896000.00$1.33M$2.62M$5.77M
Highest estimate$896000.00$1.33M$2.62M$5.77M
Number of analysts1111
A year ago—$353375.00——
Growth vs a year ago—+275.8%——
Recent rating and target changes (1)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for 20/20 Biolabs Inc.. 20/20 Biolabs Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold AIDX12 companies · 1 funds
More Medical - Care Facilities companies
TickerTypeCompanySectorExchangeMkt cap
THCTenet Healthcare CorporationHealthcareNYSE$20.9B
TTALFTerveystalo OyjHealthcareOTC$1.6B
UHSUniversal Health Services, Inc.HealthcareNYSE$9.0B
UNHLFEC HealthcareHealthcareOTC$101.9M
UNVCUnivec, Inc.HealthcareOTC$6.3M
UPDCUPD Holding Corp.HealthcareOTC$38,996
USPHU.S. Physical Therapy, Inc.HealthcareNYSE$1.4B
VLXCVeltex CorporationHealthcareOTC$3.9M
VMDViemed Healthcare, Inc.HealthcareNASDAQ$322.8M
WELL.TOWELL Health Technologies Corp.HealthcareTSX$867.7M
WEQLWellQuest Medical & Wellness CorporationHealthcareOTC$7,212
WHTCFWELL Health Technologies Corp.HealthcareOTC$735.5M
ETFs holding 20/20 Biolabs Inc.
TickerFundFund assets% of the fund
VXFVanguard Extended Market ETF$30.2B in assets0.00%

Largest holders first, then the funds most concentrated in AIDX.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

About this section

Which institutions hold 20/20 Biolabs Inc., and how their positions are changing. At a $2.2M market value, institutional positions materially move 20/20 Biolabs Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by 20/20 Biolabs Inc. executives and directors. Shares of 20/20 Biolabs Inc. have traded between $0.40 and $50.00 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for 20/20 Biolabs Inc.. Coverage tracks 20/20 Biolabs Inc. within Medical - Care Facilities (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of 20/20 Biolabs Inc.

AIDX AnalysisWeak
Past
1
Growth
1
Health
4
Profit
1
Value
1